New diarylamine KV10.1 inhibitors and their anticancer potential

Gubič, Špela (avtor), Toplak, Žan (avtor), Shi, Xiaoyi (avtor), Dernovšek, Jaka (avtor), Hendrickx, Louise Antonia (avtor), Lopes Pinheiro-Junior, Ernesto (avtor), Peigneur, Steve (avtor), Tytgat, Jan (avtor), Pardo, Luis A. (avtor), Peterlin-Mašič, Lucija (avtor), Tomašič, Tihomir (avtor)

Expression of the voltage-gated potassium channel KV10.1 (Eag1) has been detected in over 70% of human cancers, making the channel a promising new target for new anticancer drug discovery. A new structural class of KV10.1 inhibitors was prepared by structural optimisation and exploration of the structure–activity relationship of the previously published hit compound ZVS-08 (1) and its optimised analogue 2. The potency and selectivity of the new inhibitors between KV10.1 and hERG were investigated using whole-cell patch-clamp experiments. We obtained two new optimised KV10.1 inhibitors, 17a and 18b, with improved nanomolar IC50 values of 568 nM and 214 nM, respectively. Compound 17a exhibited better ratio between IC50 values for hEAG1 and hERG than previously published diarylamine inhibitors. Compounds 17a and 18b moderately inhibited the growth of the KV10.1-expressing cell line MCF-7 in two independent assays. In addition, 17a and 18b also inhibited the growth of hERG-expressing Panc-1 cells with higher potency compared with MCF-7 cells. The main obstacle for newly developed diarylamine KV10.1 inhibitors remains the selectivity toward the hERG channel, which needs to be addressed with targeted drug design strategies in the future.

• Jezik: Angleški jezik
• Ključne besede: KV10.1, ion channels, hERG, SAR, antiproliferative activity
• Vrsta gradiva: Članek v reviji
• Tipologija: 1.01 - Izvirni znanstveni članek
• Organizacija: FFA - Fakulteta za farmacijo
• Status publikacije: Objavljeno
• Različica publikacije: Objavljena publikacija
• Leto izida: 2022
• Št. strani: 27 str.
• Številčenje: Vol. 14, iss. 8, art. 1963
• PID: 20.500.12556/RUL-140829
• UDK: 577.352
• ISSN pri članku: 1999-4923
• DOI: 10.3390/pharmaceutics14091963
• COBISS.SI-ID: 121841667
• Datum objave v RUL: 19.09.2022

GUBIČ, Špela, TOPLAK, Žan, SHI, Xiaoyi, DERNOVŠEK, Jaka, HENDRICKX, Louise Antonia, LOPES PINHEIRO-JUNIOR, Ernesto, PEIGNEUR, Steve, TYTGAT, Jan, PARDO, Luis A., PETERLIN-MAŠIČ, Lucija in TOMAŠIČ, Tihomir, 2022, New diarylamine KV10.1 inhibitors and their anticancer potential. Pharmaceutics [na spletu]. 2022. Vol. 14, no. 8,  1963. [Dostopano 5 julij 2025]. DOI 10.3390/pharmaceutics14091963. Pridobljeno s: https://repozitorij.uni-lj.si/IzpisGradiva.php?lang=slv&id=140829

Gradivo je del revije

• Naslov: Pharmaceutics
• Skrajšan naslov: Pharmaceutics
• Založnik: MDPI
• ISSN: 1999-4923
• COBISS.SI-ID: 517949977

Licence

• Licenca: CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
• Povezava: http://creativecommons.org/licenses/by/4.0/deed.sl
• Opis: To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
• Začetek licenciranja: 19.09.2022

Sekundarni jezik

• Jezik: Slovenski jezik
• Ključne besede: KV10.1, ionski kanali, hERG, SAR, antiproliferativno delovanje

Projekti

• Financer: ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
• Številka projekta: N1-0098-2019
• Naslov: Odkrivanje in mehanizem delovanja novih spojin vodnic hEag1 kalijevih kanalov s protirakavim delovanjem

• Financer: ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
• Številka projekta: P1-0208-2022
• Naslov: Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin